Jim Mellon
Angel Investor
San José, Spain
Jim Mellon is a Series A investor in San José focused on Medical and Health Care. Jim Mellon
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jim Mellon invests in
Stages Jim Mellon invests in
Countries Jim Mellon invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Health Care 1 (33%)
- Life Science 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beckley Psytech
|
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assistindividuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need. | Dec 23, 2020 | |
|
Beckley Psytech
|
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assistindividuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need. | $18.9M / Series A / Dec 23, 2020 | |
|
Beckley Psytech
|
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assistindividuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need. | $14.9M / Series A / Jun 30, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jim Mellon invest in?
Jim Mellon invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jim Mellon?
Public channels for Jim Mellon include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jim Mellon last invest?
The most recent investment recorded for Jim Mellon closed in Dec 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
